Eli Lilly’s oral weight-loss drug, Foundayo, saw total prescriptions climb nearly 8%. Total prescriptions for the drug reached approximately 47,500. Novo Nordisk’s oral Wegovy recorded about 183,000 prescriptions during the same reporting period.
Foundayo is narrowing the market share gap despite its later launch. Analysts suggest current data may undercount Foundayo’s uptake from telehealth channels. The introduction of oral therapies is expanding the total obesity treatment market by attracting new patients.
Eli Lilly positions Foundayo on convenience, as it lacks the food and water restrictions required for oral Wegovy. This direct competition marks a new phase in the rivalry for the multibillion-dollar obesity market.